scholarly journals Isolation and analysis of a non-protein low molecular weight thiol-mercurial adduct from human prostate lymph node cells (LNCaP)

2020 ◽  
Vol 40 (6) ◽  
Author(s):  
Michael Gronow
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight ◽  
Anion Exchange Column ◽  
Thiol Compounds ◽  
New Class ◽  
Prostate Cells ◽  
Intermediate Fraction ◽  
Lymph Node Cells ◽  
Protein Matrices ◽  
Malignant Prostate

Abstract Thiol compounds present in human malignant prostate cells (LNCaP) were investigated after reaction with a mercurial blocking reagent. After extracting the cellular glutathione and some other low molecular weight (LMW) thiols using trichloroacetic acid the resulting the protein precipitate was extracted with buffered 8 M urea containing 2-chloromercuri-4-nitrophenol in an equimolar amount to that of the thiol present. After removing the insoluble chromatin fraction the urea soluble labeled adducts formed were chromatographed on G15 Sephadex. Three yellow coloured (A410 nm) fractions were obtained; first, the excluded protein fraction containing 16.0 ± 4.1% of the applied label followed by an intermediate fraction containing 5.9 ± 1.2%. Finally a LMW fraction emerged which contained 77.2 ± 3.7% of the total label applied and this was further analyzed by column chromatography, first on an anion exchange column and then on a PhenylSepharose 6 column to give what appeared to be a single component. LC–MS analysis of this component gave a pattern of mercuri-clusters, formed on MS ionization showing possible parent ions at 704 or 588 m/z, the former indicating that a thiol fragment of molecular weight approximately 467 could be present. No fragments with a single sulfur adduct (a 369 m/z fragment) were observed The adduct was analyzed for cysteine and other amino acids, nucleic acid bases, ribose and deoxyribose sugars, selenium and phosphorus; all were negative leading to the conclusion that a new class of unknown LMW thiol is present concealed in the protein matrices of these cells.

scholarly journals Chemical cytometry of thiols using capillary zone electrophoresis-laser induced fluorescence and TMPAB-o-M, an improved fluorogenic reagent

The Analyst ◽  
2016 ◽  
Vol 141 (4) ◽  
pp. 1325-1330 ◽  
Author(s):  
Xiao-Feng Guo ◽  
Jennifer Arceo ◽  
Bonnie Jaskowski Huge ◽  
Katelyn R. Ludwig ◽  
Norman J. Dovichi
Keyword(s):  
Molecular Weight ◽  
Capillary Zone Electrophoresis ◽  
Laser Induced Fluorescence ◽  
Low Molecular Weight ◽  
Thiol Compounds ◽  
Physiological Processes ◽  
Chemical Cytometry ◽  
Zone Electrophoresis ◽  
Capillary Zone

Low molecular weight thiol compounds play crucial roles in many physiological processes.

A New Class of Selective Low-Molecular-Weight Gelators Based on Salts of Diaminotriazinecarboxylic Acids

2006 ◽  
Vol 18 (16) ◽  
pp. 3616-3626 ◽  
Author(s):  
Olivier Lebel ◽  
Marie-Ève Perron ◽  
Thierry Maris ◽  
Sylvia F. Zalzal ◽  
Antonio Nanci ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight ◽  
New Class ◽  
Low Molecular Weight Gelators

Physicochemical properties of low molecular weight alkylated chitosans: A new class of potential nonviral vectors for gene delivery

2006 ◽  
Vol 51 (2) ◽  
pp. 140-148 ◽  
Author(s):  
Sebnem Ercelen ◽  
Xin Zhang ◽  
Guy Duportail ◽  
Christian Grandfils ◽  
Jacques Desbrières ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Gene Delivery ◽  
Physicochemical Properties ◽  
Low Molecular Weight ◽  
Nonviral Vectors ◽  
New Class

scholarly journals A STUDY OF THE DISTRIBUTION OF 2,4-DINITROBENZENE SENSITIZERS BETWEEN ISOLATED LYMPH NODE CELLS AND EXTRACELLULAR MEDIUM IN RELATION TO INDUCTION OF CONTACT SKIN SENSITIVITY

1959 ◽  
Vol 110 (2) ◽  
pp. 187-206 ◽  
Author(s):  
Herman N. Eisen ◽  
Milton Kern ◽  
William T. Newton ◽  
Ernst Helmreich
Keyword(s):  
Molecular Weight ◽  
Lymph Node ◽  
Low Molecular Weight ◽  
Skin Sensitivity ◽  
Extracellular Medium ◽  
Protein Conjugates ◽  
Protein Conjugate ◽  
Lymph Node Cells

Although induction of contact skin sensitivity by low molecular weight 2,4-dinitrobenzenes requires the formation in vivo of 2,4-dinitrophenyl-proteins, analogous protein conjugates prepared in vitro are unable to induce this hypersensitive state. Low molecular weight 2,4-dinitrobenzenes are concentrated by isolated lymph node cells, but a representative 2,4-dinitrophenyl-protein conjugate (2,4-dinitrophenyl-bovine serum albumin) was not taken up to a detectable extent by these cells. It is inferred that there exist large quantitative differences in the extent to which dinitrophenyl-proteins are localized within cells following the administration to an intact animal of (a) those simple dinitrobenzenes which are both concentrated by lymph node cells and have the capacity to form protein conjugates in vivo, and (b) 2,4-dinitrophenyl-protein conjugates prepared in vitro. It is suggested that this difference could account for the fact that a varietyof 2,4-dinitrophenyl-proteins prepared in vitro are unable to induce contact skin sensitivity.

scholarly journals Low Molecular Weight Opioid Peptide Esters Could be Developed as a New Class of Analgesics

2011 ◽  
Vol 5 ◽  
pp. PMC.S6803 ◽  
Author(s):  
Joel S. Goldberg
Keyword(s):  
Molecular Weight ◽  
Chronic Pain ◽  
Opioid Peptide ◽  
Good Manufacturing Practice ◽  
Low Molecular Weight ◽  
Clinical Use ◽  
Plasma Stability ◽  
New Class ◽  
Animal Data ◽  
Peptide Esters

Low molecular weight opioid peptide esters (OPE) could become a class of analgesics with different side effect profiles than current opiates. OPE may have sufficient plasma stability to cross the blood brain barrier (BBB), undergo ester hydrolysis and produce analgesia. OPE of dipeptides, tyr-pro and tyr-gly conjugated to ethanol have a structure similar to the anesthestic agent, etomidate. Based upon the analgesic activity of dipeptide opioids, Lipinski's criteria, and permeability of select GABA esters to cross the BBB, opioid peptides (OP) conjugated to ethanol, cholesterol or 3-glucose are lead recommendations. Preliminary animal data suggests that tyr-pro-ethyl ester crosses the BBB and unexpectedly produces hyperalgesia. Currently, there are no approved OP analgesics available for clinical use. Clinical trials of good manufacturing practice OP administered to patients suffering from chronic pain with indwelling intrathecal pumps could resolve the issue that OP may be superior to opiates and may redirect research.

Sign in / Sign up

Export Citation Format

Share Document